Filtered By:
Condition: Bleeding
Education: Academia

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 422 results found since Jan 2013.

Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting.
CONCLUSIONS: Preoperative DAPT increases the risk of CABG-related major bleeding in Japanese patients with ACS undergoing urgent CABG. PMID: 26987791 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 14, 2016 Category: Cardiology Authors: Nagashima Z, Tsukahara K, Uchida K, Hibi K, Karube N, Ebina T, Imoto K, Kimura K, Umemura S Tags: J Cardiol Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One-year outcomes from the GReek AntiPlatelet Registry (GRAPE).
CONCLUSIONS: In real-word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events. This article is protected by copyright. All rights reserved. PMID: 26990959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 16, 2016 Category: Hematology Authors: Alexopoulos D, Xanthopoulou I, Deftereos S, Hamilos M, Sitafidis G, Kanakakis I, Pentara I, Vavouranakis M, Davlouros P, Hahalis G, Goudevenos J Tags: J Thromb Haemost Source Type: research

Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention
In conclusion, in our population, F2R IVS-14 PAR1 variability does not affect risk of MACE or bleeding following PCI.
Source: Journal of Thrombosis and Thrombolysis - March 30, 2016 Category: Hematology Source Type: research

Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial
Publication date: Available online 29 April 2016 Source:American Heart Journal Author(s): C. Camaro, S.A.J. Damen, M.A. Brouwer, E. Kedhi, S.W. Lee, M. Verdoia, L. Barbieri, A. Rognoni, A.W.J. van t Hof, E. Ligtenberg, M.J. de Boer, H. Suryapranata, G. De Luca Background The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients treated with drug eluting stents (DES) is still under debate. Recent meta-analyses on≤6months versus 12months DAPT suggest that bleeding rates can be reduced, without a higher rate of thrombotic complications. In particular, the COMBO dual th...
Source: American Heart Journal - April 29, 2016 Category: Cardiology Source Type: research

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes The TRACER Trial
This study sought to investigate the relationship between BARC-classified bleeding and mortality and compared its prognostic value against 2 validated bleeding scales: TIMI (Thrombolysis In Myocardial Infarction) and GUSTO (Global Use of Strategies to Open Occluded Arteries).MethodsWe analyzed bleeding in 12,944 patients with acute coronary syndromes without ST-segment elevation, with or without early invasive strategy. The main outcome measure was all-cause death.ResultsDuring follow-up (median: 502 days), noncoronary artery bypass graft (CABG) bleeding occurred in 1,998 (15.4%) patients according to BARC (grades 2, 3, or...
Source: Journal of the American College of Cardiology - May 3, 2016 Category: Cardiology Source Type: research

Sex‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - April 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research

VARC endpoint definition compliance rates in contemporary transcatheter aortic valve implantation studies.
CONCLUSIONS: Implementation of VARC criteria in peer-reviewed manuscripts has increased over time. There remain, however, a considerable number (43%) of publications that do not report outcomes according to VARC. These data will inform the future development of VARC criteria. PMID: 27320429 [PubMed - in process]
Source: EuroIntervention - June 21, 2016 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

Sex ‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - June 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick ‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research

Mid-term study of transcatheter aortic valve implantation in an Asian population with severe aortic stenosis: two-year valve academic research consortium-2 outcomes.
CONCLUSION: Despite the unique clinical differences in an Asian population, this registry demonstrated favourable mid-term clinical and safety outcomes in Asians undergoing TAVI. PMID: 27516113 [PubMed - as supplied by publisher]
Source: Singapore Medical Journal - August 11, 2016 Category: Journals (General) Authors: Chew N, Hon JK, Yip WL, Chan SP, Poh KK, Kong WK, Teoh KL, Yeo TC, Tan HC, Tay EL Tags: Singapore Med J Source Type: research

Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
Publication date: Available online 28 August 2016 Source:The Lancet Author(s): Guillaume Cayla, Thomas Cuisset, Johanne Silvain, Florence Leclercq, Stephane Manzo-Silberman, Christophe Saint-Etienne, Nicolas Delarche, Anne Bellemain-Appaix, Grégoire Range, Rami El Mahmoud, Didier Carrié, Loic Belle, Geraud Souteyrand, Pierre Aubry, Pierre Sabouret, Xavier Halna du Fretay, Farzin Beygui, Jean-Louis Bonnet, Benoit Lattuca, Christophe Pouillot, Olivier Varenne, Ziad Boueri, Eric Van Belle, Patrick Henry, Pascal Motreff, Simon Elhadad, Joe-Elie Salem, Jérémie Abtan, Hélène Rousseau, Jean-Philippe Collet, Eric Vicaut, Gi...
Source: The Lancet - August 27, 2016 Category: Journals (General) Source Type: research

Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial
Conclusion: The efficacy and safety of CB administered for 12 months for the secondary prevention of atherothrombotic events are similar to that of CHS. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE trial; ClinicalTrials.gov Identifier:NCT02126982).
Source: Journal of Cardiovascular Pharmacology and Therapeutics - October 4, 2016 Category: Cardiology Authors: Ntalas, I. V., Kalantzi, K. I., Tsoumani, M. E., Bourdakis, A., Charmpas, C., Christogiannis, Z., Dimoulis, N., Draganigos, A., Efthimiadis, I., Giannakoulas, G., Giatrakos, I., Giogiakas, V., Goumas, G., Hatziathanasiou, G., Kazakos, E., Kipouridis, N., Tags: Clinical Study Source Type: research

Trial design: Rivaroxaban for the prevention of major cardiovascular events post transcatheter aortic valve replacement: rationale and design of the GALILEO study
Conclusions GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy-based strategy in subjects without need of chronic oral anticoagulation.
Source: American Heart Journal - October 31, 2016 Category: Cardiology Source Type: research

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI. PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Conclusions GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy–based strategy in subjects without need of chronic oral anticoagulation.
Source: American Heart Journal - November 25, 2016 Category: Cardiology Source Type: research

Prospective comparison between three TAVR devices: ACURATE neo vs. CoreValve vs. SAPIEN XT. A single heart team experience in patients with severe aortic stenosis
ConclusionsIn a “real world” registry, ACT compared favorably against the well‐studied SXT and MCV devices in both safety and efficacy. MCV implantation was associated with lower device success rates and higher rates of new permanent pacemaker implantation. © 2016 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - December 27, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Tannas Jatene, Antonio Castro ‐Filho, Rafael A. Meneguz‐Moreno, Dimytri A. Siqueira, Alexandre A.C. Abizaid, Auristela I.O. Ramos, Magaly Arrais, David C.S. Le Bihan, Rodrigo B.M. Barretto, Adriana C. Moreira, Amanda G.M.R. Sousa, J. Eduardo Sousa Tags: Valvular and Structural Heart Diseases Source Type: research